Bionano Stock Analysis

BNGO -  USA Stock  

USD 2.15  0.14  6.11%

The big decline in price over the last few months for Bionano Genomics could raise concerns from institutional investors as the firm it trading at a share price of 2.15 on 10,457,800 in volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Bionano Genomics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.31. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Bionano Genomics partners.
Continue to Trending Equities.

Bionano Stock Analysis 

 
Refresh
The Bionano Genomics stock analysis report makes it easy to digest most publicly released information about Bionano Genomics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Bionano Stock analysis module also helps to analyze the Bionano Genomics price relationship with some important fundamental indicators such as market cap and management efficiency.

Bionano Stock Analysis Notes

About 25.0% of the company shares are held by institutions such as insurance companies. The book value of Bionano Genomics was currently reported as 1.3. The company recorded a loss per share of 0.25. Bionano Genomics had not issued any dividends in recent years. Bionano Genomics, Inc., a genome analysis company, provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. The company was founded in 2006 and is headquartered in San Diego, California. Bionano Genomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 147 people. For more info on Bionano Genomics please contact Erik Holmlin at 858 888 7600 or go to https://bionanogenomics.com.

Bionano Genomics Quarterly Cost of Revenue

3.5 MillionShare

Bionano Genomics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bionano Genomics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bionano Genomics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bionano Genomics generated a negative expected return over the last 90 days
Bionano Genomics has high historical volatility and very poor performance
The company reported the previous year's revenue of 15.67 M. Net Loss for the year was (61.22 M) with profit before overhead, payroll, taxes, and interest of 2.77 M.
Bionano Genomics currently holds about 326.07 M in cash with (58.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.13.
Latest headline from www.marketscreener.com: Bionano Genomics Announces Record Daily Attendance for 2022 Symposium with 63 percent Increase Relative to Last Year - marketscreener.com

Bionano Genomics Upcoming and Recent Events

Earnings reports are used by Bionano Genomics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bionano Genomics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report22nd of March 2022
Next Earnings Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End22nd of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Bionano Largest EPS Surprises

Earnings surprises can significantly impact Bionano Genomics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-13
2021-03-31-0.045-0.040.00511 
2021-11-04
2021-09-30-0.0575-0.07-0.012521 
2020-11-13
2020-09-30-0.0567-0.08-0.023341 
View All Earnings Estimates

Bionano Genomics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Bionano Genomics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Bionano Genomics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Bionano Genomics specific information freely available to individual and institutional investors to make a timely investment decision.
12th of January 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
30th of December 2021
Entry into a Material Definitive Agreement
View
23rd of December 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
4th of November 2021
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
19th of October 2021
Financial Statements and Exhibits. Completion of Acquisition or Disposition of Assets
View
12th of October 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
4th of August 2021
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
11th of June 2021
Submission of Matters to a Vote of Security Holders
View

Bionano Genomics Thematic Classifications

In addition to having Bionano Genomics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Measuring and Control IdeaMeasuring and Control
USA Equities from Measuring and Control industry as classified by Fama & French

Bionano Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 897.51 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bionano Genomics's market, we take the total number of its shares issued and multiply it by Bionano Genomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Bionano Profitablity

Bionano Genomics' profitability indicators refer to fundamental financial ratios that showcase Bionano Genomics' ability to generate income relative to its revenue or operating costs. If, let's say, Bionano Genomics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Bionano Genomics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Bionano Genomics' profitability requires more research than a typical breakdown of Bionano Genomics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(1.28) (1.38) 
Return on Average Equity(2.88) (3.11) 
Return on Invested Capital(4.80) (5.18) 
Return on Sales(4.08) (4.41) 

Management Efficiency

The entity has return on total asset (ROA) of (18.06) % which means that it has lost $18.06 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (34.37) %, meaning that it created substantial loss on money invested by shareholders. Bionano Genomics management efficiency ratios could be used to measure how well bionano genomics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -1.38. The value of Return on Average Equity is estimated to slide to -3.11. Bionano Genomics Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 64.28 Million
Last ReportedProjected for 2022
Book Value per Share 0.39  0.42 
Enterprise Value over EBIT(10.80) (11.08) 
Enterprise Value over EBITDA(11.38) (11.68) 
Price to Book Value 15.47  13.49 
Tangible Assets Book Value per Share 0.45  0.46 
Enterprise Value539.3 M581.9 M
Tangible Asset Value59.6 M64.3 M

Technical Drivers

As of the 23rd of January, Bionano Genomics shows the mean deviation of 3.24, and Risk Adjusted Performance of (0.29). Bionano Genomics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Bionano Genomics, which can be compared to its rivals. Please confirm Bionano Genomics coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Bionano Genomics is priced correctly, providing market reflects its regular price of 2.15 per share. Please also double-check Bionano Genomics total risk alpha, which is currently at (0.81) to validate the company can sustain itself at a future point.

Bionano Genomics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Bionano Genomics more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Bionano Genomics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bionano Genomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bionano Genomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bionano Genomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Wong Vincent Jungfai over a month ago via Macroaxis 
Acquisition by Wong Vincent Jungfai of 122054 shares of Bionano Genomics subject to Rule 16b-3
Stewart Christopher P over two months ago via Macroaxis 
Exercise or conversion by Stewart Christopher P of 22500 shares of Bionano Genomics subject to Rule 16b-3
Shams Soheil over three months ago via Macroaxis 
Acquisition by Shams Soheil of 5325378 shares of Bionano Genomics subject to Rule 16b-3
Domain Partners Viii Lp over three months ago via Macroaxis 
Conversion by Domain Partners Viii Lp of 591184 shares of Bionano Genomics
Linney Yvonne over three months ago via Macroaxis 
Acquisition by Linney Yvonne of 40751 shares of Bionano Genomics subject to Rule 16b-3
Shippy Richard over six months ago via Macroaxis 
Acquisition by Shippy Richard of 400000 shares of Bionano Genomics subject to Rule 16b-3
Stewart Christopher P over six months ago via Macroaxis 
Exercise or conversion by Stewart Christopher P of 25000 shares of Bionano Genomics subject to Rule 16b-3
Oldakowski Mark over six months ago via Macroaxis 
Acquisition by Oldakowski Mark of 240000 shares of Bionano Genomics subject to Rule 16b-3
Chaubey Alka over six months ago via Macroaxis 
Bionano Genomics exotic insider transaction detected
Stewart Christopher P over six months ago via Macroaxis 
Acquisition by Stewart Christopher P of 8000 shares of Bionano Genomics subject to Rule 16b-3
Chaubey Alka over a year ago via Macroaxis 
Acquisition by Chaubey Alka of 300000 shares of Bionano Genomics subject to Rule 16b-3
Stewart Christopher P over a year ago via Macroaxis 
Acquisition by Stewart Christopher P of 225000 shares of Bionano Genomics subject to Rule 16b-3

Bionano Genomics Predictive Daily Indicators

Bionano Genomics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bionano Genomics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Bionano Genomics Forecast Models

Bionano Genomics time-series forecasting models is one of many Bionano Genomics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bionano Genomics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Bionano Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bionano Genomics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bionano shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Bionano Genomics. By using and applying Bionano Stock analysis, traders can create a robust methodology for identifying Bionano entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(3.92) (4.23) 
Gross Margin 0.29  0.30 
Profit Margin(4.35) (4.69) 
Bionano Genomics, Inc., a genome analysis company, provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. The company was founded in 2006 and is headquartered in San Diego, California. Bionano Genomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 147 people.

Current Bionano Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bionano analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bionano analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
12.0Strong Buy4Odds
Bionano Genomics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Bionano analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bionano stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bionano Genomics, talking to its executives and customers, or listening to Bionano conference calls.
Bionano Analyst Advice Details

Bionano Stock Analysis Indicators

Bionano Genomics stock analysis indicators help investors evaluate how Bionano Genomics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bionano Genomics shares will generate the highest return on investment. By understating and applying Bionano Genomics stock analysis, traders can identify Bionano Genomics position entry and exit signals to maximize returns.
Fifty Two Week Low2.1100
Fifty Two Week High15.6900
Average Daily Volume Last 10 Day8.38M
Average Daily Volume In Three Month9.08M
Fifty Day Average3.5386
Two Hundred Day Average5.3829
Continue to Trending Equities. Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Bionano Stock analysis

When running Bionano Genomics price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine Bionano Genomics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.